Trial · NCT01162733

Loading Vancomycin Doses in the Emergency Department

NCT01162733, Not applicable, Completed, Christiana Care Health Services; results first posted 2014-03-13

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Loading Vancomycin Doses in the Emergency Department. Trials, record NCT01162733. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01162733

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Loading Vancomycin Doses in the Emergency Department
NCT number: NCT01162733
Status: Completed
Phases: Not applicable
Enrollment: 99 participants, actual
Lead sponsor: Christiana Care Health Services
Conditions: Infectious Disease
Interventions: Vancomycin, Vancomycin
First posted: 2010-07-15
Last updated: 2014-03-13
Results first posted: 2014-03-13

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Percentage of Participants First Achieving Therapeutic Levels at 36 Hours	36 hours	The objective is to determine if therapeutic levels were reached more rapidly with the implementation of an initial vancomycin loading dose of 30 mg/kg as compared to 15mg/kg.
Primary	Percentage of Participants First Achieving Therapeutic Levels at 12 Hours	12 hours	Percentage of patients reaching a therapeutic level defined as greater than 15 mcg/mL

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Percentage of Participants First Achieving Therapeutic Levels at 36 Hours	36 hours		percentage of participants	NUMBER
PRIMARY	Percentage of Participants First Achieving Therapeutic Levels at 12 Hours	12 hours		percentage of participants	NUMBER

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Percentage of Participants First Achieving Therapeutic Levels at 36 Hours	Study Drug 1	20	percentage of participants
Percentage of Participants First Achieving Therapeutic Levels at 36 Hours	Study Drug 2	18	percentage of participants
Percentage of Participants First Achieving Therapeutic Levels at 12 Hours	Study Drug 1	3	percentage of participants
Percentage of Participants First Achieving Therapeutic Levels at 12 Hours	Study Drug 2	34	percentage of participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Study Drug 1	49
Overall Study	STARTED	Study Drug 2	50
Overall Study	COMPLETED	Study Drug 1	22
Overall Study	COMPLETED	Study Drug 2	25
Overall Study	NOT COMPLETED	Study Drug 1	27
Overall Study	NOT COMPLETED	Study Drug 2	25

Source ClinicalTrials.gov

Adverse events8

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Allergic Reaction	Immune system disorders	Study Drug 1	2	49	2
other	Allergic Reaction	Immune system disorders	Study Drug 2	2	50	2
other	Flushing	Skin and subcutaneous tissue disorders	Study Drug 1	1	49	1
other	Flushing	Skin and subcutaneous tissue disorders	Study Drug 2	1	50	1
serious	New onset Atrial fibrillation	Cardiac disorders	Study Drug 1	0	49	0
serious	New onset Atrial fibrillation	Cardiac disorders	Study Drug 2	1	50	1
serious	Renal failure	Renal and urinary disorders	Study Drug 1	0	49	0
serious	Renal failure	Renal and urinary disorders	Study Drug 2	1	50	1

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Study Drug 1
Total, all-cause mortality	Study Drug 2
Total, other adverse events	Study Drug 1	3	49
Total, other adverse events	Study Drug 2	3	50
Total, serious adverse events	Study Drug 1	0	49
Total, serious adverse events	Study Drug 2	2	50

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Study Drug 1 vs Study Drug 2: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01162733

GET https://conductscience.org/api/trials/v1/NCT01162733/registered

API reference For AI assistants